JAFRON(300529)2021-08-02 16:00Financial Performance - The company's operating revenue for the reporting period was ¥1,188,254,809.14, representing a 36.63% increase compared to the previous year[13]. - The net profit attributable to shareholders was ¥620,140,698.34, reflecting a 40.74% year-over-year growth[13]. - The net profit after deducting non-recurring gains and losses was ¥584,793,617.60, up by 40.28% from the same period last year[13]. - The net cash flow from operating activities reached ¥492,315,765.05, marking a 44.88% increase compared to the previous year[13]. - The total assets at the end of the reporting period were ¥4,491,865,044.04, a 38.95% increase from the end of the previous year[13]. - The weighted average return on net assets was 22.94%, an increase of 3.85% compared to the previous year[13]. - The company's revenue for the reporting period reached ¥1,188,254,809.14, a year-on-year increase of 36.63% driven by enhanced market promotion and R&D investment[57]. - The net profit for the period was ¥619,052,068.06, reflecting a 40.93% increase year-on-year, primarily due to increased sales revenue[57]. - The total liabilities amounted to ¥1,264,404,250.38, significantly up from ¥383,060,209.90 at the end of 2020, representing a rise of approximately 230.66%[135]. Research and Development - Future outlook indicates a commitment to research and development of new products and technologies, enhancing its competitive edge[6]. - Research and development investment during the reporting period was 51.17 million yuan, accounting for 4.31% of total operating revenue, with a year-on-year growth of 65.62%[43]. - The company adopts a combined research and development model, focusing on independent and joint R&D to enhance efficiency and reduce risks, collaborating with institutions like the Chinese Academy of Sciences and several universities[24][25]. - The company obtained 5 invention patents, 12 utility model patents, and 5 design patents during the first half of 2021, with a total of 221 authorized patents by the end of the reporting period[43]. - The company has a strong R&D team with 197 master's and 9 doctoral degree holders, covering various fields related to medical engineering[42]. Market Expansion and Strategy - The company is actively pursuing market expansion strategies, including potential mergers and acquisitions[6]. - The company has established several subsidiaries to enhance its operational capabilities and market reach[4]. - The company has established a marketing network covering over 5,900 hospitals nationwide, with more than 4,500 promotional activities conducted in the uremia field during the reporting period[48]. - The company has formed an overseas expert committee to enhance the global application of its blood adsorption therapy, collaborating with top international experts[49]. - The company aims to leverage its technological advantages and strong marketing capabilities to continuously develop a series of blood purification products targeting critical diseases[39]. Product Performance - The sales revenue from disposable blood perfusion devices was ¥1,048,501,200, accounting for 88.33% of the company's main business income, with a year-over-year growth of 32.85%[19]. - The sales revenue from disposable plasma bilirubin adsorbers was ¥61,537,200, representing 5.18% of the main business income, with an impressive growth of 82.95%[20]. - The DX-10 blood purification machine generated sales revenue of ¥26,733,100, which is 2.25% of the main business income, showing a significant increase of 162.42%[21]. - The sales revenue of the blood dialysis powder liquid products reached 21.0183 million yuan, accounting for 1.77% of the company's main business income, with a year-on-year growth of 71.68%[23]. - The company’s HA380 blood perfusion device achieved sales revenue of 18.17 million yuan, with a remarkable year-on-year growth of 1157.88% in the critical care field[49]. Corporate Governance and Compliance - The financial report emphasizes the importance of accurate and complete financial disclosures, ensuring transparency[1]. - The board of directors and management have confirmed the authenticity and completeness of the financial report[1]. - The company has obtained a total of 17 medical device registration certificates, with 4 new additions since the end of 2020, demonstrating its commitment to compliance and product development[39]. - The company has developed a systematic quality control capability, ensuring compliance with ISO13485 standards since 2005[45]. - The company has established a strict quality control system, ensuring compliance with national standards and has not experienced any medical incidents due to product quality issues since its inception[85]. Social Responsibility - The company is committed to fulfilling its social responsibilities and adhering to environmental standards[6]. - The company actively participated in social responsibility initiatives, donating 5 million CNY to the China Hepatitis Prevention Foundation and 3 million CNY in medical supplies to flood-affected areas[93]. Financial Management - The company completed the issuance of convertible bonds, resulting in a net cash inflow from financing activities of ¥656,964,138.06, a 342.98% increase year-on-year[57]. - The total cash inflow from financing activities was CNY 1,187,979,656.94, a significant increase of 926.58% due to the issuance of convertible bonds[58]. - The company has engaged in entrusted financial management, with a total of RMB 120 million allocated to bank and brokerage financial products, all of which are currently not overdue[78]. - The company reported a loss of ¥34,783.87 from its investments during the reporting period[66]. - The company has not changed the use of raised funds, with a cumulative change ratio of 0.00%[72]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 36,701[115]. - The largest shareholder, Dong Fan, holds 43.58% of the shares, totaling 350,828,772 shares[117]. - The company did not conduct any repurchase transactions among the top ten ordinary shareholders during the reporting period[118]. - The total number of shares held by the top ten shareholders includes significant holdings by Hong Kong Central Clearing Limited (3.85%) and Tang Xianmin (2.64%)[117]. - The company confirmed that there are no arrangements for differential voting rights among shareholders[118]. Operational Highlights - The company has maintained its registered address and contact information without changes during the reporting period[8]. - The company did not distribute cash dividends or bonus shares for the first half of 2021[89]. - The company has not sold any significant assets or equity during the reporting period, indicating stability in its asset management[81][82]. - The company did not engage in any major related party transactions during the reporting period[102]. - The company has no derivative investments or entrusted loans reported during the period, reflecting a conservative financial strategy[79][80].